# Thymosin Alpha-1: sepsis results

> Thymosin Alpha-1 | Peptide Materials Research Review — Peptide Materials Research Review examines Thymosin Alpha-1, immune modulation, the ETASS and TESTS sepsis trials, and safety limits.

An intact peptide and a plausible immune mechanism can support a serious experiment. The later survival result still has to be faced.

## A prepared molecule meets a complex illness

Thymosin Alpha-1 is a 28-amino-acid peptide; the synthetic form, thymalfasin, matches its sequence. It has been used as a medicine in other countries, while US marketing approval has not been granted. The [comprehensive literature review](https://pubmed.ncbi.nlm.nih.gov/33362999/) describes that clinical history and the local injection-site reactions most often reported.

The phrase “immune support” makes me impatient because it obscures the problem being treated. Sepsis involves infection and a harmful response throughout the body. Researchers are interested in both restoring exhausted defences and restraining damaging inflammation. The [review of immune mechanisms in cancer care](https://pubmed.ncbi.nlm.nih.gov/31555601/) describes this combination of stimulating and regulatory actions, drawing on preclinical and clinical work.

With this peptide, my preoccupation with materials reaches its limit. Matching a sequence can establish which molecule entered a study. The patient’s illness, other care and response determine whether that molecule helps.

## ETASS / TESTS

[ETASS](https://pubmed.ncbi.nlm.nih.gov/23327199/) studied 361 patients with severe sepsis. At 28 days, mortality was 26.0% with Thymosin Alpha-1 and 35.0% with comparison care. The result encouraged further investigation, although the unstratified mortality comparison did not reach conventional statistical significance.

The larger [2025 TESTS trial](https://pubmed.ncbi.nlm.nih.gov/39814420/) enrolled 1,106 adults with sepsis across 22 centres. It used random allocation, placebo and double blinding. Mortality at 28 days was 23.4% with Thymosin Alpha-1 and 24.1% with placebo, with no statistically significant difference.

The earlier separation in those death counts looks hopeful even to me. The later trial deserves more influence on a sepsis claim than that hope does. Both trials concern very sick patients; neither supplies evidence for generally “boosting” a healthy person’s immunity.

![Two sepsis trials comparing 28-day mortality with Thymosin Alpha-1 and control](images/sepsis-counts.svg)

*ETASS: 361 patients with severe sepsis. TESTS: 1,106 adults with sepsis. Neither established a clear overall survival benefit; the trials are separate comparisons.*

## The COVID-19 association

A [retrospective review of 76 severe COVID-19 cases](https://pubmed.ncbi.nlm.nih.gov/32442287/) associated treatment with lower mortality and improvements in depleted or exhausted T cells. Because it examined care already given, treatment allocation could reflect differences in patients’ starting condition and other care.

That is a reason to investigate the association carefully. It gives weaker grounds for attributing survival to the peptide than a blinded randomized comparison does. Nor can one infection’s result simply be carried across to another illness.

## Tolerability

People report fewer seasonal infections, easier recovery, no noticeable change, local redness or itching, and occasional flu-like feelings. These are anecdotal accounts, not clinical evidence. Feeling more resilient supplies no dependable measurement of immune function.

The [clinical review](https://pubmed.ncbi.nlm.nih.gov/33362999/) describes local irritation, redness and discomfort as common adverse effects in the literature. Evidence in pregnancy and breastfeeding is limited. Autoimmune disease and transplant care raise theoretical concerns because altering immune activity may work against an existing clinical goal; these concerns do not establish that the peptide causes those harms.

Unknown research material adds uncertainty about identity and cleanliness. Even a perfectly identified sample would leave the largest sepsis trial’s disappointing efficacy finding exactly where it is. I won’t pad a sepsis claim with reassurance imported from a different disease.

---

An independent review of how peptide materials become evidence—literature and context, never a storefront or clinical instruction.